CROX
Crocs, Inc.
CROX has the edge over NIO overall, supported by stronger modeled upside and lower modeled downside.
NIO
NIO Inc.
NIO's outlook is improving, though it still trails on the overall score.
CROX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CROX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Stable | |
| Unavailable |
NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
CROX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $97.23 | -38% |
| Forward | 9.9x | $157 | — |
| Fair | 11x | $146 | -7.1% |
| Current | 12x | $157 | — |
| Expensive | 22x | $286 | +82% |
Historical ranges are pointers, not guarantees.
CROX's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.9x next year's earnings.
NIO PE Valuation
NIO has no meaningful PE right now: it lost money over the past year.
CROX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CROX, with profitability improving.
NIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect NIO's losses to shrink, with revenue growing.
CROX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.91 | +21% |
| Q3 2026 | $13.15 | +344% |
| Q2 2026 | $11.33 | +213% |
| Q1 2026 | -$1.62 | -110% |
| Q4 2025 | -$1.50 | -109% |
| Q3 2025 | $2.96 | -79% |
| Q2 2025 | $3.62 | -73% |
| Q1 2025 | $16.21 | +26% |
| Q4 2024 | $15.88 | +24% |
CROX has the edge over NIO on earnings quality, reporting a profit while its opponent remains loss making.
NIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.29 | +$1.45 |
| Q1 2026 | -$0.60 | +$1.16 |
| Q4 2025 | -$1.06 | +$0.60 |
| Q3 2025 | -$1.59 | +$0.02 |
| Q2 2025 | -$1.74 | -$0.10 |
| Q1 2025 | -$1.76 | +$0.06 |
| Q4 2024 | -$1.66 | +$0.21 |
| Q3 2024 | -$1.61 | +$0.32 |
NIO is still losing money, but far less than before: $0.29 per share over the past year, against $1.93 at its worst in late 2023.
CROX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +4.6% |
| Q2 2026 | $1.2B | +2.6% |
| Q1 2026 | $921.5M | -1.7% |
| Q4 2025 | $957.6M | -3.2% |
| Q3 2025 | $996.3M | -6.2% |
| Q2 2025 | $1.1B | +3.4% |
| Q1 2025 | $937.3M | -0.1% |
| Q4 2024 | $989.8M | +3.1% |
CROX's revenue grew through 2023 and has held roughly level since: $1B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +7.2 points |
| Q2 2026 | 24% | +61 points |
| Q1 2026 | 22% | -2 points |
| Q4 2025 | 15% | -4.9 points |
| Q3 2025 | 21% | -4.6 points |
| Q2 2025 | -37% | -67 points |
| Q1 2025 | 24% | -0.3 points |
| Q4 2024 | 20% | -1.6 points |
CROX has the edge over NIO on profitability, with a higher operating margin.
NIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +69% |
| Q1 2026 | $3.8B | +112% |
| Q4 2025 | $5.2B | +76% |
| Q3 2025 | $3.3B | +17% |
| Q2 2025 | $2.9B | +9% |
| Q1 2025 | $1.8B | +21% |
| Q4 2024 | $3B | +15% |
| Q3 2024 | $2.8B | -2.1% |
NIO has the edge over CROX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.1% | +24 points |
| Q1 2026 | -1.2% | +52 points |
| Q4 2025 | 2.3% | +33 points |
| Q3 2025 | -16% | +12 points |
| Q2 2025 | -26% | +4 points |
| Q1 2025 | -53% | +1.1 points |
| Q4 2024 | -31% | +8.1 points |
| Q3 2024 | -28% | -2.6 points |
NIO's operating margin was −2.1% last quarter, up 24 points from the same quarter a year ago.
CROX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $275.5M | +22% |
| Q2 2026 | $331M | +23% |
| Q1 2026 | -$98.9M | -$16.3M |
| Q4 2025 | $246.4M | -19% |
| Q3 2025 | $226.2M | -19% |
| Q2 2025 | $269.2M | -30% |
| Q1 2025 | -$82.6M | -$39.3M |
| Q4 2024 | $303.4M | -5.3% |
CROX generated $754M in free cash flow over the past year, up 5.3% from the year before.
NIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$2.1B |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | +$391.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$2.1B | +$73.9M |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$391.3M | -386% |
| Q2 2024 | -$2.2B | +$337.9M |
NIO has the edge over CROX on cash flow, with more consistent year-over-year improvement.
CROX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -1.7M shares |
| 1 year | -11% | -6M shares |
| 3 years | -22% | -13.7M shares |
| 5 years | -24% | -15.4M shares |
| Available history | -33% | -23.8M shares |
CROX has the edge over NIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $250M |
| Q2 2026 | $256.2M |
| Q1 2026 | — |
| Q4 2025 | $180.2M |
| Q3 2025 | $208M |
| Q2 2025 | $133.3M |
| Q1 2025 | $60.9M |
| Q4 2024 | $226.3M |
CROX spent $686M buying back its own shares over the past year, up 9.2% from the year before.
NIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +15.6M shares |
| 1 year | +12% | +267M shares |
| 3 years | +51% | +844M shares |
| 5 years | +60% | +933M shares |
| Available history | +143% | +1.5B shares |
NIO has 2.5B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NIO hasn't bought back shares in the past year.
CROX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 5.8x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
CROX's net debt is about 1.1 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
NIO Net Leverage
NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CROX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.6 | Neutral |
| Stochastic | 88.0 | Overbought |
CROX's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
NIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 6.9 | Oversold |
NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
CROX PE vs Consumer Cyclical Sector
| Metric | CROX | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 34% below |
| PE % | 57 | 47 | 10 pts above |
CROX is trading at 12x earnings, a 34% discount to the Consumer Cyclical sector's median of 18x.
NIO PE vs Consumer Cyclical Sector
NIO has no meaningful PE right now: it lost money over the past year.
CROX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $132.6 | 18% above |
| 20 week MA | $129.2 | 21% above |
| 50 week MA | $109.7 | 43% above |
| 100 week MA | $102.8 | 53% above |
| 200 week MA | $110.2 | 42% above |
CROX has the edge over NIO on trend strength, trading above more of its moving averages.
NIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 9.2% below |
| 20 week MA | $4.01 | 24% below |
| 50 week MA | $4.81 | 37% below |
| 100 week MA | $4.85 | 37% below |
| 200 week MA | $6.03 | 49% below |
NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
CROX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.3 | $62.7 | +52% |
| 2021 | $62.7 | $123.5 | +97% |
| 2022 | $123.5 | $103.0 | -17% |
| 2023 | $103.0 | $93.4 | -9.3% |
| 2024 | $93.4 | $110.7 | +19% |
| 2025 | $110.7 | $91.6 | -17% |
| 2026 YTD | $91.6 | $156.9 | +71% |
CROX has the edge over NIO on returns for 2026, with the stronger performance.
NIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.42 | $45.8 | +1791% |
| 2021 | $45.8 | $30.5 | -33% |
| 2022 | $30.5 | $11.0 | -64% |
| 2023 | $11.0 | $9.07 | -17% |
| 2024 | $9.07 | $4.48 | -51% |
| 2025 | $4.48 | $5.10 | +14% |
| 2026 YTD | $5.10 | $3.05 | -40% |
NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.